Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
CHICAGO - MAIA Biotechnology, Inc. (NYSE American:MAIA), a clinical-stage biotech company with a market capitalization of approximately $56 million, has dosed the first patient in Taiwan in the expansion phase of its THIO-101 Phase 2 trial for advanced non-small cell lung cancer (NSCLC), according to a company press release. InvestingPro analysis shows the company maintains a strong liquidity position, with cash reserves exceeding debt obligations.
The trial is evaluating ateganosine (THIO) in heavily pre-treated patients who have previously failed treatment with checkpoint inhibitors and chemotherapy. Two treatment arms are being studied: ateganosine sequenced with cemiplimab (Libtayo) and ateganosine monotherapy.
As of May 15, 2025, the median overall survival for the 22 patients in the third-line treatment was 17.8 months, with a 95% confidence interval lower bound of 12.5 months. The treatment has been generally well-tolerated in the trial’s heavily pre-treated population, the company stated.
The expansion into Taiwan represents a key milestone for MAIA, providing access to a larger patient pool. Screening for the trial is currently ongoing in Europe and Asia.
NSCLC represents a significant oncology market, valued at $34.1 billion in 2024 and projected to reach $68.8 billion by 2033, according to data cited in the release.
The THIO-101 trial is designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. Its primary objectives include evaluating safety and tolerability of ateganosine and assessing clinical efficacy using Overall Response Rate as the primary clinical endpoint.
Ateganosine is a telomere-targeting agent that induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death, according to the company. With analyst price targets ranging from $10.27 to $14.00, significantly above current trading levels, investors seeking deeper insights into MAIA’s financial health and growth prospects can access additional exclusive analysis through InvestingPro, which offers 8 more key investment tips for this emerging biotech company.
In other recent news, MAIA Biotechnology, Inc. announced a stock purchase agreement with Prevail Partners, LLC, allowing the company to issue up to $587,905 of its common stock. The agreement includes an upfront payment and subsequent monthly payments, with a cap on the number of shares issued. Additionally, MAIA Biotechnology has partnered with Roche to explore the combination of its telomere-targeting agent, ateganosine, with Roche’s checkpoint inhibitor for treating various cancers. The company also reported positive developments from its Phase 2 trial for ateganosine, showing a partial response in a patient with advanced non-small cell lung cancer (NSCLC). This trial indicated a median overall survival of 17.8 months, significantly surpassing the standard chemotherapy outcomes. Furthermore, MAIA Biotechnology appointed two hepatocellular carcinoma (HCC) experts to its Scientific Advisory Board to guide its upcoming trial of ateganosine in HCC patients. These developments highlight MAIA’s ongoing efforts in advancing cancer treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.